Malter et al. retrospectively analyzed the complex treatment regimens of 13 anti-GAD65 epilepsy patients and found that the seizure and cognitive response to immunotherapies were poor, with the most frequently achieved seizure response (≥ 50% reduction) occurring in only 45% of patients under intensive corticosteroid treatment (median 19 g methylprednisolone equivalent) [11]. Here, GAD2 is linked to epilepsy.